- Stocks
- Healthcare
- OTC: NWBO

Price (delayed)

$0.7138

Market cap

$740.38M

P/E Ratio

4.2

Dividend/share

N/A

EPS

$0.17

Enterprise value

$766.9M

The equity has soared by 74% YoY and by 24% from the previous quarter

NWBO's net income has surged by 128% year-on-year but it is down by 20% since the previous quarter

The EPS has soared by 127% YoY but it has contracted by 19% from the previous quarter

What are the main financial stats of NWBO

Market
Valuations
Earnings

Shares outstanding

1.04B

Market cap

$740.38M

Enterprise value

$766.9M

Price to earnings (P/E)

4.2

Price to book (P/B)

N/A

Price to sales (P/S)

582.63

EV/EBIT

5.44

EV/EBITDA

5.4

EV/Sales

623.49

Revenue

$1.23M

EBIT

$141.05M

EBITDA

$142.09M

Free cash flow

-$50.78M

Per share
Balance sheet
Liquidity

EPS

$0.17

Free cash flow per share

-$0.05

Book value per share

-$0.09

Revenue per share

$0

TBVPS

$0.03

Total assets

$27.52M

Total liabilities

$119.19M

Debt

$31.35M

Equity

-$91.67M

Working capital

-$90.98M

Debt to equity

-0.34

Current ratio

0.07

Quick ratio

0.05

Net debt/EBITDA

0.19

Margins
Efficiency
Dividend

EBITDA margin

11,551.7%

Gross margin

100%

Net margin

10,972.1%

Operating margin

-4,399.2%

Return on assets

426.5%

Return on equity

N/A

Return on invested capital

N/A

Return on capital employed

N/A

Return on sales

11,467.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Northwest Biotherapeutics stock price performed over time

Intraday

-0.86%

1 week

-2.22%

1 month

0.61%

1 year

-42.44%

YTD

1.97%

QTD

13.3%

How have Northwest Biotherapeutics's revenue and profit performed over time

Revenue

$1.23M

Gross profit

$1.23M

Operating income

-$54.11M

Net income

$134.96M

Gross margin

100%

Net margin

10,972.1%

NWBO's net margin has soared by 132% YoY but it is down by 24% QoQ

NWBO's net income has surged by 128% year-on-year but it is down by 20% since the previous quarter

NWBO's operating income is up by 48% YoY but it is down by 19% from the previous quarter

NWBO's operating margin is up by 41% year-on-year but it is down by 13% since the previous quarter

What is Northwest Biotherapeutics's growth rate over time

What is Northwest Biotherapeutics stock price valuation

P/E

4.2

P/B

N/A

P/S

582.63

EV/EBIT

5.44

EV/EBITDA

5.4

EV/Sales

623.49

The EPS has soared by 127% YoY but it has contracted by 19% from the previous quarter

The equity has soared by 74% YoY and by 24% from the previous quarter

The P/S is 53% above the 5-year quarterly average of 381.0 but 4.6% below the last 4 quarters average of 609.5

Northwest Biotherapeutics's revenue has decreased by 10% YoY but it has increased by 5% QoQ

How efficient is Northwest Biotherapeutics business performance

The ROS has soared by 134% YoY but it has contracted by 23% from the previous quarter

The return on assets has surged by 127% year-on-year but it has declined by 19% since the previous quarter

What is NWBO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NWBO.

How did Northwest Biotherapeutics financials performed over time

The total assets is 77% smaller than the total liabilities

NWBO's total liabilities has dropped by 69% year-on-year and by 21% since the previous quarter

The total assets has declined by 10% since the previous quarter and by 4.3% year-on-year

NWBO's debt is 134% higher than its equity

The equity has soared by 74% YoY and by 24% from the previous quarter

NWBO's debt is up by 21% YoY but it is down by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.